What is the difference between Paragon and other pharma companies? What makes Paragon special? Why should scientific innovators work with us? Here's why:?
Paragon Biosciences
生物技术研究
Chicago，Illinois 4,173 位关注者
Paragon creates and supports focused, visionary companies to accelerate life science innovations.
关于我们
Paragon is a global life science leader that creates, builds and funds innovative biology-based companies. We use biology to accelerate scientific breakthroughs to solve some of society's most challenging medical problems.
- 网站
-
https://www.paragonbiosci.com
Paragon Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Chicago，Illinois
- 类型
- 私人持股
- 创立
- 2010
地点
-
主要
获取路线
330 N Wabash Ave
Suite 3500
US，Illinois，Chicago，60611
Paragon Biosciences员工
-
Sheridan Chaney
Strategic Communications | Healthcare | BioTech | Crisis Communications| External Affairs
-
Timothy Cunniff
Executive Vice President, Research & Development and Chief Scientific Officer, Paragon Biosciences LLC
-
Stephen Wanaski
SVP, Research & Exploratory Development at Paragon Biosciences
-
Robert Fincannon
Director Of Information Technology
动态
-
Biotech investments, including initial public offerings and mergers and acquisitions, ramped up this year. With patent cliffs looming, pharma companies are seeking partnerships to explore new therapeutic options and innovation. At Paragon, we use biology to accelerate scientific breakthroughs to treat and cure disease. With that focus, we seek out areas of unmet needs and identify the best science to find therapeutic solutions. One area of focus that we excel in is neurology.
-
Congratulations to our very own Timothy Cunniff, Executive Vice President of Research and Development, on this outstanding achievement!
The College of Pharmacy is proud to award Tim Cunniff, PharmD ’89, with the inaugural Ara G. Paul Philanthropic Distinction Award. This award honors the late Dean Emeritus Ara Paul and recognizes those who embody his philanthropic spirit. Dr. Cunniff’s gracious contributions to the College have made a profound impact on past and present students. Read why he gives back in this release: https://bit.ly/4ehUB0u
-
-
Cole Ikkala, vice president of strategic capital, is one of the newer faces at Paragon. This former Division 1 ice hockey player and Boston transplant joined Paragon over a year ago. Working alongside leaders with decades of experience, Cole shares his thoughts about the work being done at Paragon. https://lnkd.in/gnEpmC4j
Catching Up with Cole
https://www.youtube.com/
-
Outstanding work Harmony Biosciences!
Today, Harmony Biosciences is presenting new data, providing a comprehensive pipeline update, and highlighting progress from our strategic acquisitions at our Investor Day. For more information: https://lnkd.in/eQMKJWwE
-
-
Check out this event to learn more about narcolepsy on World Narcolepsy Day, Sunday, Sept. 22.
??? ONE WEEK AWAY! Tune in on Sunday, September 22, 2024 at 9am ET via Project Sleep's YouTube channel for the #WorldNarcolepsyDay featured event: How Storytelling Brings Narcolepsy to Light. ??? In this panel discussion, 9-year NFL veteran, Josh Andrews, the Director of External Communication for Harmony Biosciences, Christian Emering, and President & CEO of Project Sleep, Julie Flygare, JD, will discuss the challenges and opportunities for increasing #narcolepsy awareness, especially via media. ?? Learn more & add this event to your calendar: https://lnkd.in/ggXWieHZ
-
-
Congratulations Harmony Biosciences on your achievements to help patients in need!
This past year has been a remarkable journey for Harmony Biosciences, marked by exciting changes and progress. With strategic acquisitions and advancements in our pipeline, we’ve remained steadfast in our commitment to keeping patients at the heart of everything we do and translating innovative #science into therapeutic possibilities. Join us as we reflect on the past year and express our gratitude to our team members, investors, supporters, and community. #Biosciences #scientificInnovation
-
Fantastic news from Harmony Biosciences! Congratulations!
Today we announced our acquisition of Epygenix Therapeutics, which accelerates our growth strategy by adding a rare epilepsy franchise to our expanding late-stage pipeline of innovative CNS assets and furthers our commitment to delivering promising treatments to patients with high unmet medical needs. Read more: https://lnkd.in/eghw4kyF ?